Keros Therapeutics share price logo

Keros Therapeutics

NASDAQ: KROS

$11.03

-0.20

(-1.78%)

as on

Keros Therapeutics Stock Performance

as on August 29, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $10.58
    $11.16
    downward going graph

    4.08%

    Downside

    1.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.69
    $22.55
    downward going graph

    12.15%

    Downside

    104.44%

    Upside

    downward going graph

Keros Therapeutics share price movements today

Previous Close
$11.23
Open
$11.15
Volume
402.0K
Market Cap
$220.5M
Day's Low - High
$10.58 - $11.16
52 Week Low - High
$9.69 - $22.55

Keros Therapeutics Historical Returns

1 Month Return
+ 11.52 %
3 Month Return
-1.4 %
1 Year Return
-26.36 %
3 Year Return
-68.46 %
5 Year Return
-67.89 %

Keros Therapeutics Stock Fundamentals & Key Indicators

Check Keros Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$220.5M

EPS (TTM)

-5.22

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-96.9M

Revenue (TTM)

15.0M

Profit Margin

0.00%

Return On Equity TTM

-17.16%

Keros Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Keros Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Keros Therapeutics image
Keros Therapeutics
BUY$220.5M-67.89%NA0.00%NA
Revolution Medicines image
Revolution Medicines
BUY$46.2B675.69%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$138.7B173.88%31.9286.04%NA
Moderna image
Moderna
BUY$59.7B-62.65%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$85.8B21.77%19.984.86%0.44%

Stock Returns calculator for Keros Therapeutics Stock including INR - Dollar returns

The Keros Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Keros Therapeutics investment value today

Current value as on today

₹78,239

Returns

-₹21,761

(-21.76%)

Returns from Keros Therapeutics Stock

-₹27,672 (-27.67%)

Dollar Impact

₹5,911 (+5.91%)

Analyst Recommendation on Keros Therapeutics Stock

Based on 6 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'BUY' rating for Keros Therapeutics. Average target price of $19.83

Keros Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Keros Therapeutics.

What analysts predicted

44.38%UPSIDE

Target Price

$19.83

Current Price

$11.03

Analyzed by

6 Analysts

Target

$19.83

Keros Therapeutics target price $19.83, a slight upside of 44.38% compared to current price of $11.03. According to 6 analysts rating.

Indian Investors' Interest in Keros Therapeutics Stock

Search interest for Keros Therapeutics Stock has increased by 15% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:15% versus previous 30 day period

Keros Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
3
211
18
14
0
0
18
Gross Profit
0
0
0
2
211
17
13
0
0
-
Operating Income
-48
-50
-58
-53
152
-39
-15
-29
-25
-30
EBITDA
-42
-44
-52
-29
158
-32
-8
-24
-23
-28
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-43
-45
-52
-45
158
-32
-8
-24
-23
-28
Income Tax Expense
0
-
-
0
10
-2
-1
-1
-
2
Net Income
-43
-45
-52
-46
148
-30
-7
-23
-23
-28
Net Profit Margin
-51944.58%
-122316.22%
-13648.45%
-1513.02%
70.27%
-168.96%
-51.04%
-6093.77%
-6459.95%
-158.03%

Keros Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
10
10
2
20
20
0
3
244
Gross Profit
0
-7
0
20
-1
0
3
242
Operating Income
-1
-10
-46
-56
-114
-169
-210
70
EBITDA
0
-11
-44
-56
-104
-152
-185
93
Interest Expense
0
0
0
0
0
-
-
-
Depreciation
0
0
0
0
0
0
1
1
Income Before Tax
-1
-12
-45
-56
-104
-152
-187
91
Income Tax Expense
0
0
0
2
0
0
0
4
Net Income
-1
-12
-45
-58
-104
-152
-187
87
Net Profit Margin
-13.35%
-123.44%
-1814.44%
-292.26%
-523.40%
-101319.21%
-5277.55%
35.65%

Keros Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-45
-52
-46
148
-30
-7
-23
-23
-28
Operating Cash Flow
-39
-30
-46
161
-29
3
-27
-3
-20
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
3
155
75
0
0
0
-378
-2
-3
Change in Cash
-36
125
29
160
-30
3
-406
-5
-23

Keros Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-45
-58
-104
-152
-187
87
Operating Cash Flow
-15
-36
-62
-70
-124
-160
107
Investing Cash Flow
0
0
-1
-1
-2
-1
-1
Financing Cash Flow
0
296
28
120
178
391
-378
Change in Cash
-16
258
-34
49
51
229
-272

Mutual Funds that own Keros Therapeutics Stock

Check out the Mutual Funds with significant holdings in Keros Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
4.098972%
812711
Federated Hermes MDT Series
2.514315%
498518
Fidelity Salem Street Trust
1.663024%
329731
TIAA-CREF Funds
1.50109%
297624
Fidelity Concord Street Trust
1.107675%
219621
See all

Global Institutional Holdings in Keros Therapeutics

Funds
Holdings
Eric Andersen
11.04%
Vanguard
5.07%
iShares
5.02%
Dimensional
0.88%
Bridgeway
0.71%
See all

Insights on Keros Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 472.8% return, outperforming this stock by 500.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 18.3% return, outperforming this stock by 87.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, KROS stock has moved down by -69.0%

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
OrganisationKeros Therapeutics
Headquarters1050 Waltham Street, Lexington, MA, United States, 02421
IndustryBiotechnology
CEODr. Jasbir S. Seehra Ph.D.
E-voting on sharesClick here to vote

Key Management of Keros Therapeutics

Name

Title

Dr. Jasbir S. Seehra Ph.D.

President, CEO & Director

Ms. Esther Cho J.D.

Chief Legal Officer & Secretary

Ms. Annita Tanini

VP, Corporate Controller and Interim Principal Financial & Accounting Officer

Justin Frantz

Head of Investor Relations

Dr. Lorena Lerner Ph.D.

Chief Scientific Officer

FAQs

What is Keros Therapeutics share price today?

Keros Therapeutics share price today is $11.03 as on at the close of the market. Keros Therapeutics share today touched a day high of $11.16 and a low of $10.58.

What is the 52 week high and 52 week low for Keros Therapeutics share?

Keros Therapeutics share touched a 52 week high of $22.55 on and a 52 week low of $9.69 on . Keros Therapeutics stock price today i.e. is closed at $11.03,which is 51.09% down from its 52 week high and 13.83% up from its 52 week low.

What is Keros Therapeutics's market capitalisation today?

Keros Therapeutics market capitalisation is $0.00T as on .

How to invest in Keros Therapeutics Stock (KROS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Keros Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Keros Therapeutics Shares that will get you 0.1360 shares as per Keros Therapeutics share price of $11.03 per share as on August 29, 2026 at 8:46 am IST.

What is the minimum amount required to buy Keros Therapeutics Stock (KROS) from India?

Indian investors can start investing in Keros Therapeutics (KROS) shares with as little as ₹95.38 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.80 in Keros Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Keros Therapeutics share’s latest price of $11.03 as on August 29, 2026 at 8:46 am IST, you will get 0.9066 shares of Keros Therapeutics. Learn more about fractional shares .

What are the returns that Keros Therapeutics has given to Indian investors in the last 5 years?

Keros Therapeutics stock has given -67.89% share price returns and 30.19% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?